mySugr Demonstrates Clinically Significant Impact on Diabetes Management for High Risk Population

mySugr Demonstrates Clinically Significant Impact on Diabetes Management for High Risk Population

Retrospective data analysis published by ProSciento and mySugr at ATTD in Paris

SAN DIEGO, February 15, 2017 – mySugr and ProSciento, Inc., announced today data from a retrospective observational clinical research study that demonstrates consistent use of the mySugr app provides an opportunity for improved blood glucose control in high risk populations. Data was presented at the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD), February 15-18 in Paris.

The mySugr app, a registered class I medical device application, was developed to make logging of metabolic control data appealing and useful in day-to-day life, and has developed into a market leading digital diabetes service with a rapidly growing user base of nearly one million registered users.

“Mobile healthcare services have long been seen as a field with potential. The use of digital health apps continues to grow at a rapid rate, but their scientific impact on a patient’s therapy has remained largely unvalidated. We feel obligated to invest in scientific research to better understand the effect mySugr has on our users’ therapy,” said Frank Westermann, mySugr’s Chief Executive Officer, who has lived with type 1 diabetes for 20 years.

The study monitored 440 randomly selected high risk patients over a six-month period, analyzing blood glucose control and High Blood Glucose Index (HBGI) levels. After just one month of use the mean blood glucose was drastically lowered. After six months of use, the results show a nearly 20% drop in mean blood glucose (-17.88%, from 9.0% to 7.7%, p < 1.0e-23) and more than 60% drop in HBGI (62.34%, from 5.39 to 3.36, p < 1e-10). The results also show a large and significant reduction of the size of the group at high to medium risk of severe events (with an HBGI ≥ 4.5), by more than 40% (43.73%, p < 2.2e-16). Expressed using estimated A1c, the effect is -1.3% points in A1c, or a nearly 14% reduction. “The data from this initial retrospective observational study suggests that consistent use of the mySugr app may contribute to significant improvements of blood glucose control in high risk populations,” said Dr. Marcus Hompesch, ProSciento’s Chairman and CEO. “mySugr’s commitment to conduct clinical research to validate the efficacy of their applications is a testimony to the company’s vision and pursuit of making a difference in the lives of people with diabetes.” The e-poster “Significant Improvement of Blood Glucose Control in a High Risk Population of Type 1 Diabetes Using a Mobile Health App – a Retrospective Observational Study” by Dr. Marcus Hompesch and team is available on the ATTD Conference website.

About mySugr
Founded in 2012, by people with diabetes for people with diabetes, mySugr has offices in Vienna, Austria and the San Diego area. The mySugr app is widely recognized as one of the most successful mobile health apps for diabetes with a rapidly growing user base of nearly one million users worldwide. The company’s digital diabetes solutions showcase a stand-out user experience that combines diabetes coaching, therapy management, automated data tracking, and seamless integration with a growing number of medical devices. mySugr is available in 51 countries and 13 languages. For more information, please visit mysugr.com/press.

About ProSciento Inc.
ProSciento is a full scope clinical R&D service provider exclusively focused on diabetes, obesity and NAFLD/NASH. The company works with clients worldwide to support their metabolic drug and device candidates as an intellectual partner to develop and implement strategies from IND/CTA and NDA/ANDA filing to post-market and investigator initiated studies, including clinical development, regulatory, licensing and partnering support.

The company has completed more than 250 metabolic clinical studies, representing more early phase type 1 and type 2 diabetes clinical trials than any other U.S. provider.1 The team has supported the development of more than 15 metabolic drugs and devices on the market worldwide, and, in 2015, facilitated one of the year’s largest early-stage licensing deals. For more information, visit prosciento.com.

For further information, please contact:

mySugr Inc.
Scott Johnson | Communication Lead USA
Tel.: +1 612 234-7752
Email: scott.johnson@mysugr.com

ProSciento, Inc.

Abby Devine, Corporate Communications
Tel: +1 858 663-6148
Email: abby.devine@prosciento.com